ARTH 1.00 Arch Therapeutics, Inc.
| Range: | 0.1701-18.0 | Vol Avg: | 6081 | Last Div: | 0 | Changes: | 0.13 |
| Beta: | 3.61 | Cap: | 0.00B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Jan 02 2013 | Empoloyees: | 8 | ||
| CUSIP: | 03939W109 | CIK: | 0001537561 | ISIN: | US03939W2089 | Country: | US |
| CEO: | Dr. Terrence W. Norchi M.D. | Website: | https://www.archtherapeutics.com | ||||
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow